На этой странице перечислены больницы направления «Гинекология» (включая Intrauterine Device (IUD) Placement) в Ченнаи, Индия, включая Apollo Hospitals, Greams Road, Gleneagles Global Hospital, Dr. Rela Institute and Medical Centre, SIMS Hospital и другие.
Спросите нас о «Intrauterine Device (IUD) Placement» в Ченнаи, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 8 аккредитованных больниц (Гинекология) в Ченнаи, Индия
Рекомендуем🇮🇳 Apollo Hospitals, Greams Road
Больница занимает 1-е место в этом списке по указанному рейтингу (4.7/5, 125 отзывов).
🇮🇳 Gleneagles Global Hospital
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 112 отзывов).
🇮🇳 Dr. Rela Institute and Medical Centre
Больница занимает 3-е место в этом списке по указанному рейтингу (4.7/5, 108 отзывов).
🇮🇳 SIMS Hospital
Больница занимает 4-е место в этом списке по указанному рейтингу (4.6/5, 20 отзывов).
🇮🇳 Sankara Nethralaya
Больница занимает 5-е место в этом списке по указанному рейтингу (4.4/5, 220 отзывов).
🇮🇳 Apollo First Med Hospitals, Kilpauk
Больница занимает 6-е место в этом списке по указанному рейтингу (4.4/5, 76 отзывов).
🇮🇳 MIOT International
Больница занимает 7-е место в этом списке по указанному рейтингу (4.4/5, 200 отзывов).
🇮🇳 MGM Healthcare
Больница занимает 8-е место в этом списке по указанному рейтингу (3.7/5, 34 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Гинекология» указано среди её специализаций и она находится в Ченнаи, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «intrauterine device (iud) placement» в Ченнаи, Индия?
Выбор подходящей больницы для «intrauterine device (iud) placement» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Гинекология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Intrauterine Device (IUD) Placement»
IUD (intrauterine device) insertion is a highly effective, long-acting reversible contraception (LARC) procedure with a success rate exceeding 99% in preventing pregnancy, and is also used therapeutically to manage heavy menstrual bleeding, endometriosis-related pain, and dysmenorrhea. The procedure is performed by experienced gynaecologists in accredited hospitals across India and the UAE, offering international patients access to world-class reproductive healthcare at a fraction of the cost found in Western countries. GAF Healthcare connects patients with JCI- and NABH-accredited facilities in India and JCI- and DHA-licensed clinics in Dubai and Abu Dhabi, providing seamless, end-to-end medical travel coordination for women seeking safe, discreet, and affordable gynaecological care. Hospital Stay: 0–1 days (outpatient or brief observation; no inpatient admission required in the vast majority of cases) • Total Stay in Country (Fit-to-Fly): 1–3 days (most patients are fit for international travel within 24–72 hours post-procedure, subject to absence of complications such as significant cramping, bleeding, or suspected perforation) • Success Rate: 99%+ (contraceptive efficacy); >85% patient satisfaction for therapeutic indications including heavy menstrual bleeding reduction with the levonorgestrel-releasing IUS
Clinical Overview
An intrauterine device (IUD) is a small, T-shaped medical implant placed inside the uterine cavity by a trained gynaecologist to provide long-acting reversible contraception or targeted uterine therapy. There are two principal categories: copper IUDs (non-hormonal, e.g., Copper-T 380A or Multiload Cu-375), which work by releasing copper ions that are spermicidal and alter the uterine environment to prevent fertilisation and implantation; and hormonal intrauterine systems (IUS), most notably the levonorgestrel-releasing IUS (LNG-IUS) available in 52 mg (Mirena), 19.5 mg (Kyleena), and 13.5 mg (Jaydess/Skyla) formulations, which thicken cervical mucus, suppress endometrial proliferation, and in many users suppress ovulation partially or fully. Copper IUDs are effective for 5–12 years and serve as the most effective emergency contraception when inserted within 120 hours of unprotected intercourse. The LNG-IUS (52 mg) is licenced for up to 8 years for contraception and is the first-line pharmacological treatment for idiopathic heavy menstrual bleeding (HMB), reducing menstrual blood loss by up to 94% at 12 months, representing a non-surgical alternative to endometrial ablation or hysterectomy. From a physiological standpoint, IUD insertion involves traversing the cervical canal and placing the device within the uterine fundus under sterile conditions. The procedure is typically preceded by uterine sounding to measure cavity length (optimal fundal placement requires a uterine depth of ≥6 cm for standard devices). In nulliparous patients or those with cervical stenosis, adjunctive measures such as cervical priming with misoprostol (400 mcg vaginally or sublingually 2–4 hours prior), a paracervical block using 1–2% lidocaine, or ultrasound guidance may be employed to enhance safety and patient comfort. Uterine perforation, the most serious procedural risk, occurs in approximately 1–2 per 1,000 insertions and is significantly mitigated by operator experience and real-time ultrasound guidance — a standard of care routinely offered at GAF Healthcare's partner institutions. The clinical indications for IUD/IUS therapy have expanded considerably beyond contraception. Current evidence-based guidelines from the WHO, FSRH (Faculty of Sexual and Reproductive Healthcare), and ACOG support LNG-IUS use in the management of endometriosis (as adjunctive post-surgical therapy or primary medical management), adenomyosis (reducing dysmenorrhea and HMB), endometrial hyperplasia without atypia (as an alternative to oral progestogens), and as endometrial protection in peri- and postmenopausal women on oestrogen-only hormone replacement therapy. International patients travelling to India and the UAE benefit from centres experienced in complex insertions, including post-caesarean, post-abortion, and post-partum (including immediate post-placental) placements.
Who is a Candidate?
• IDEAL CANDIDATES FOR IUD/IUS INSERTION: • Women seeking long-acting reversible contraception (LARC) who prefer to avoid daily pill compliance or systemic hormonal exposure • Women with heavy menstrual bleeding (HMB; defined as >80 mL blood loss per cycle or subjectively distressing blood loss) seeking the LNG-IUS as a first-line medical alternative to surgery • Patients with endometriosis or adenomyosis seeking hormonal suppression of endometrial tissue with localised uterine delivery of levonorgestrel • Patients with endometrial hyperplasia without atypia requiring progestogen therapy • Women requiring oestrogen-only HRT who need endometrial protection via intrauterine progestogen • Women who require emergency contraception (copper IUD insertion within 120 hours of unprotected intercourse) • Breastfeeding mothers (copper IUD and low-dose LNG-IUS are both WHO Medical Eligibility Criteria Category 1 or 2 in lactating women) • Nulliparous women (insertion is feasible with appropriate cervical preparation; not a contraindication) • REQUIRED PRE-PROCEDURAL DIAGNOSTICS & WORKUP: • Pelvic examination and bimanual assessment to determine uterine position (anteverted, retroverted, or mid-position) and size • Transvaginal ultrasound (TVUS) to confirm uterine cavity dimensions, rule out uterine anomalies (e.g., septate uterus, fibroids distorting the cavity, polyps), and serve as real-time guidance during insertion if elected • Cervical screening (Pap smear / HPV co-test) — must be up to date prior to insertion • Sexually transmitted infection (STI) screening: endocervical swabs for Chlamydia trachomatis and Neisseria gonorrhoeae (NAAT-based testing); active cervicitis is a contraindication until treated • Urine pregnancy test (day of procedure) • Full blood count (FBC) in patients with HMB to assess for iron-deficiency anaemia • Coagulation screen if history suggests bleeding disorder (e.g., von Willebrand disease workup — APTT, vWF antigen, vWF activity, Factor VIII) • Sonohysterography or hysteroscopy if suspected intrauterine pathology requires characterisation prior to device placement • CONTRAINDICATIONS (Absolute — WHO MEC Category 4): • Confirmed or suspected pregnancy • Unexplained abnormal uterine bleeding (prior to investigation) • Distorted uterine cavity (large submucous fibroids, severe uterine anomalies that preclude correct placement) • Active pelvic inflammatory disease (PID) or puerperal sepsis • Active sexually transmitted infection (cervicitis due to gonorrhoea or chlamydia — until successfully treated) • Cervical or endometrial cancer (uninvestigated or confirmed) • Uterine cavity depth <6 cm (for standard adult devices) • Gestational trophoblastic disease with persistently elevated beta-hCG (relative contraindication for LNG-IUS) • Known copper allergy or Wilson's disease (contraindication specific to copper IUDs) • Active liver disease or liver tumour (contraindication specific to LNG-IUS due to hepatic metabolism of levonorgestrel)
Treatment Options & Approaches
IUD insertion encompasses several clinical approaches and device types, selected based on the patient's indication, parity, uterine anatomy, and personal preference. The following outlines the complete spectrum available at GAF Healthcare's partner centres: 1. STANDARD COPPER IUD INSERTION (Non-hormonal, in-office procedure) The copper IUD (most commonly Copper-T 380A, effective for 10–12 years, or Multiload Cu-375, effective for 5 years) is inserted using a narrow insertion tube (typically 3.5–4.4 mm outer diameter) passed through the cervical os into the fundal uterine cavity. The procedure takes 5–15 minutes under local anaesthesia (paracervical block) or without anaesthesia. A no-touch technique (Hicks technique) is employed at high-volume centres to minimise contamination risk. The strings are trimmed to 2–3 cm from the external cervical os to facilitate removal and self-monitoring. 2. LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) INSERTION The LNG-IUS (Mirena 52 mg / Kyleena 19.5 mg / Jaydess 13.5 mg) is inserted via a dedicated introducer system. The Mirena system uses a 4.4 mm outer diameter introducer tube; its mechanism of action is primarily local (intrauterine levonorgestrel concentrations are 1,000-fold higher than serum concentrations), making systemic side effects minimal compared to oral or injectable progestogens. Selection among formulations is guided by duration of use required, uterine cavity size (Kyleena and Jaydess have smaller frames, preferred for nulliparous patients or small cavities), and whether HMB treatment is the primary indication (only the 52 mg LNG-IUS is licenced for HMB management). 3. ULTRASOUND-GUIDED INSERTION (Advanced Technique) Real-time transabdominal or transvaginal ultrasound guidance during insertion is the advanced standard of care offered at GAF Healthcare's partner JCI/NABH-accredited hospitals for: • Nulliparous patients with cervical stenosis • Patients with a retroverted or acutely anteflexed uterus • Post-caesarean section patients with lower segment scarring • Patients with submucosal fibroids requiring precise fundal placement • Any case where the first unaided attempt is unsuccessful Ultrasound guidance reduces the perforation rate from ~1–2/1,000 to <0.5/1,000 in experienced hands and confirms optimal fundal positioning immediately post-insertion. 4. HYSTEROSCOPY-ASSISTED IUD PLACEMENT (Minimally Invasive) In patients with suspected or confirmed uterine cavity pathology (polyps, septa, small fibroids), office or operative hysteroscopy is performed immediately prior to IUD insertion. This allows direct visualisation, treatment of intrauterine pathology, and placement of the IUD under direct endoscopic view — a combined approach that maximises efficacy and safety. Modern slim-diameter hysteroscopes (Bettocchi office hysteroscope, 5 Fr operating channel; Storz Compact Hysteroscope) allow this to be performed without general anaesthesia in the outpatient setting. 5. IMMEDIATE POST-PLACENTAL AND POST-ABORTION IUD INSERTION At GAF Healthcare's partner centres experienced in postpartum family planning, copper IUDs and LNG-IUS can be inserted within 10 minutes of placental delivery (post-placental) or immediately following first- or second-trimester medical or surgical abortion. Post-placental insertion carries a higher expulsion rate (~15–25%) compared to interval insertion (~5%), which is fully discussed with patients during informed consent. The clinical benefit of leveraging an already-dilated cervix often outweighs the expulsion risk for motivated patients. 6. CERVICAL PREPARATION PROTOCOLS For nulliparous patients or those with cervical stenosis, pharmacological cervical priming is performed with: • Misoprostol 400 mcg vaginally or sublingually (2–4 hours pre-insertion) • Mifepristone 200 mg orally 24–48 hours prior (emerging evidence, particularly in nulliparous patients) • Mechanical osmotic dilators (Dilapan-S or laminaria) in select complex cases Paediatric/mini-sized IUDs (e.g., Flexi-T 300, Copper-T 200B, Gynefix frameless intrauterine copper implant) are alternatives for patients with a uterine cavity depth of 5–6 cm.
Восстановление
PRE-ARRIVAL & TELECONSULTATION (2–4 weeks before travel) • GAF Healthcare coordinates a secure video consultation between the patient and the treating gynaecologist at the destination centre • Upload and review of prior medical records: previous Pap smear results, STI screening, pelvic ultrasound reports, and menstrual history • Determination of the optimal timing of insertion (preferably during the first 7 days of the menstrual cycle to confirm non-pregnant status and ease cervical access, though insertion can occur at any point in the cycle when pregnancy is excluded) • Selection of device type (copper IUD vs. LNG-IUS formulation) and insertion technique (standard vs. ultrasound-guided vs. hysteroscopy-assisted) • Prescription of pre-procedural cervical priming medication (misoprostol) or NSAIDs (ibuprofen 400–600 mg or naproxen 500 mg orally 1 hour before procedure) for pain management, dispatched or prescribed locally prior to travel • GAF Healthcare initiates e-Medical visa (India) or entry/tourist visa (UAE) documentation support DAY OF ARRIVAL (Day 0) • Airport pickup arranged by GAF Healthcare dedicated coordinator • Check-in to partner hotel or hospital-affiliated accommodation • Briefing by GAF Healthcare patient coordinator; translation services confirmed DAY 1 — PRE-PROCEDURE ASSESSMENT (Day of or day before insertion) • In-person consultation with consultant gynaecologist • On-site diagnostics (same-day turnaround): urine pregnancy test, pelvic examination, transvaginal ultrasound, STI swabs (NAAT), FBC if indicated • Uterine sounding performed in clinic to measure cavity depth and confirm suitability • Informed consent process: risks, benefits, alternatives, string check instructions, and expulsion warning signs discussed in detail • Anaesthesia plan confirmed (paracervical block; oral analgesia; IV sedation for anxious or complex patients in selected centres) DAY 1 OR DAY 2 — THE INSERTION PROCEDURE (Duration: 5–20 minutes) • Patient positioned in dorsal lithotomy; bimanual examination repeated • Cervix visualised with bivalve speculum; antiseptic (povidone-iodine or chlorhexidine) applied to ectocervix • Tenaculum applied to anterior lip of cervix for traction and uterine straightening • Paracervical block administered if elected (1% lidocaine, 5 mL bilaterally at 3 o'clock and 9 o'clock positions) • Uterine sound passed to confirm cavity depth and direction • IUD loaded into insertion tube and advanced to the fundus using the withdrawal/plunger technique; fundal placement confirmed with ultrasound • Strings trimmed to 2–3 cm; speculum removed • Patient monitored for 15–30 minutes post-insertion for vasovagal response, severe cramping, or abnormal bleeding • Discharge with written aftercare instructions: expected light cramping and spotting for 24–72 hours; NSAIDs as needed; activity as tolerated; avoid penetrative sexual intercourse for 24 hours DAY 2–3 — POST-PROCEDURE RECOVERY & OBSERVATION • Follow-up clinical check (in-person or teleconsultation) at 24–48 hours to confirm absence of fever, excessive bleeding (>a heavy period), or severe pelvic pain • GAF Healthcare coordinator available 24/7 for patient queries • Transvaginal ultrasound at 48-hour check if any doubt about position • Most patients resume normal activity, light work, and walking within 24 hours • Avoidance of tampons and menstrual cups for the first menstrual cycle post-insertion to reduce expulsion risk FIT-TO-FLY ASSESSMENT (Day 2–3) • Patients are generally fit to fly within 24–72 hours provided: (a) No signs of pelvic inflammatory disease (fever >38°C, purulent discharge, uterine tenderness) (b) No suspected perforation (c) Bleeding is manageable (≤heavy period flow) (d) No vasovagal or haemodynamic instability • Recommendation: long-haul flights (>6 hours) should be preceded by a confirmed 48-hour observation period and a clearance ultrasound FOLLOW-UP (4–6 weeks post-insertion) • First string check and device position confirmation: patient performs self-string check or attends a local gynaecologist at home country • GAF Healthcare provides a comprehensive discharge summary, device insertion record, and referral letter for the patient's home-country gynaecologist • Annual string check recommended thereafter; device replaced at recommended interval (5, 8, or 10–12 years depending on device type)
Возможные риски
IUD insertion is one of the safest gynaecological procedures performed worldwide, but patients must be fully informed of the following procedure-specific and device-specific risks: Uterine perforation: The most serious procedural complication, occurring in approximately 1–2 per 1,000 insertions in experienced hands. Risk is elevated in breastfeeding women (due to uterine involution and atrophy), those with a retroverted uterus, and insertions performed within 6 weeks postpartum. Ultrasound-guided insertion at GAF Healthcare's partner centres reduces this risk substantially. Management ranges from conservative observation (if the device is partially perforated and within the myometrium) to laparoscopic retrieval for intraperitoneal displacement. Expulsion: Spontaneous partial or complete expulsion occurs in approximately 2–10% of users within the first year, most commonly during menstruation in the first 3 months. Risk is higher in nulliparous patients, patients with heavy menstrual bleeding at baseline, post-placental insertion, and younger age. Patients are taught to perform monthly string self-checks. Pelvic inflammatory disease (PID): The absolute risk of PID attributable to IUD insertion is approximately 1 in 1,000 insertions (0.1%), confined primarily to the first 20 days post-insertion and associated with pre-existing asymptomatic lower genital tract infection. Pre-insertion STI screening is mandatory at all GAF Healthcare partner centres to mitigate this risk. Prophylactic antibiotics are not routinely recommended by FSRH/WHO guidelines for low-risk screened patients. Pain and vasovagal syncope: Cervical dilation during insertion triggers a parasympathetic vasovagal response in a minority of patients, causing transient bradycardia, hypotension, nausea, and syncope. All GAF Healthcare partner centres have protocols for supine positioning, intravenous access, and monitoring for a minimum of 15–30 minutes post-procedure. Device-specific hormonal effects (LNG-IUS): Irregular spotting and light bleeding ('unscheduled bleeding') is nearly universal in the first 3–6 months following LNG-IUS insertion and resolves in the majority of patients. By 12 months, approximately 20% of LNG-IUS users will experience amenorrhoea (absence of periods), which is a therapeutic benefit rather than a clinical concern, though patients must be counselled to avoid interpreting this as pregnancy. Ectopic pregnancy risk: IUDs do not increase the absolute risk of ectopic pregnancy when compared to using no contraception. However, in the rare event of contraceptive failure, the ratio of ectopic-to-intrauterine pregnancies is elevated. Any patient who conceives with an IUD in situ should be assessed urgently with beta-hCG and transvaginal ultrasound to exclude ectopic implantation. International travel-specific consideration: Patients travelling internationally should carry their IUD insertion record card and the GAF Healthcare discharge letter translated into English (and the local language of their home country where relevant) to facilitate management of any delayed complications at their home healthcare system.
Почему GAF Healthcare
GAF Healthcare provides comprehensive, end-to-end non-medical travel support for international patients travelling to India or the UAE for IUD insertion, ensuring that the logistical burden of medical travel is entirely managed by a dedicated coordination team. VISA ASSISTANCE — INDIA: GAF Healthcare's visa team prepares and submits the e-Medical Visa application for India on behalf of the patient and one accompanying attendant. The Indian e-Medical Visa (e-MV) allows a stay of up to 60 days (triple-entry) and is typically approved within 48–72 hours. Required documents (invitation letter from the partner hospital, passport copy, recent photograph) are collected and formatted by the GAF team. Patients from GCC countries, the UK, EU, and most African and Southeast Asian nations are eligible. Visa on Arrival (VOA) processing support is also available at select Indian airports for eligible nationalities. VISA ASSISTANCE — UAE (DUBAI / ABU DHABI): Patients from over 50 nationalities (including all EU/EEA countries, the UK, USA, Canada, Australia, and many GCC residents) receive a complimentary 30- or 90-day visa on arrival in the UAE. For patients requiring a formal medical visa or a visa from a UAE embassy abroad, GAF Healthcare coordinates with the partner hospital's international patient department to issue the required medical letter and appointment confirmation. UAE healthcare facilities are fully licensed by the Dubai Health Authority (DHA) or the Department of Health – Abu Dhabi (DoH), and GAF Healthcare provides documentation to support visa issuance where required. AIRPORT TRANSFERS: Private, air-conditioned vehicle transfers are arranged for arrival and departure at all major airports: Indira Gandhi International (Delhi), Chhatrapati Shivaji Maharaj International (Mumbai), Kempegowda International (Bengaluru), Dubai International (DXB), and Abu Dhabi International (AUH). Drivers are briefed on the patient's condition and arrival details. Wheelchair assistance is coordinated with the airline for patients with mobility limitations. MEDICAL INTERPRETERS & TRANSLATORS: GAF Healthcare maintains a network of qualified medical interpreters for Arabic, French, Russian, Swahili, Amharic, Yoruba, and other major languages. Interpreters are present during the gynaecological consultation, the procedure itself (if required), and the discharge counselling session to ensure that informed consent, post-procedure instructions, and string-check guidance are communicated with full comprehension. ACCOMMODATION: GAF Healthcare arranges accommodation for the patient and up to one attendant at vetted hotels within 10–20 minutes of the partner hospital. Given that IUD insertion is an outpatient procedure with a 1–3 day recovery stay, accommodation is typically a standard double room at a 3- or 4-star property. All accommodation options include daily breakfast, reliable Wi-Fi, and proximity to pharmacy services for post-procedural analgesic procurement. DEDICATED PATIENT COORDINATOR: Each patient is assigned a named GAF Healthcare coordinator who serves as the single point of contact from the first inquiry through to post-discharge follow-up. The coordinator communicates via WhatsApp, email, or phone in the patient's preferred language, manages all appointment scheduling, facilitates teleconsultation with the treating gynaecologist, and provides a 24/7 emergency contact number throughout the patient's stay.
Частые вопросы о процедуре «Intrauterine Device (IUD) Placement»
What is the cost of IUD insertion in India compared to the UAE?
How long do I need to stay in India or the UAE before I am fit to fly home after IUD insertion?
What is the success rate of IUD insertion, and how effective is it?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «intrauterine device (iud) placement» в Ченнаи, Индия
Найдите лучшие больницы для «intrauterine device (iud) placement» в Ченнаи, Индия
На этой странице представлено 8 больниц в Ченнаи, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Intrauterine Device (IUD) Placement» в Ченнаи, Индия
Сколько больниц направления «Гинекология» представлено в Ченнаи, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Ченнаи, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Intrauterine Device (IUD) Placement» в Ченнаи, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.